There is some interest in using IGF1-LR3 to reduce the side effects of glucocorticoids and thus allow for more effective therapy
Obesity reviews : an official journal of the International Association for the Study of Obesity, 12 (8), 593-601 PMID: 21401851
The SCALE trial measured outcomes at week 56, showing the 8% average body weight reduction
Integrating GLP-1s into a comprehensive treatment plan GLP-1 medications work best when theyre part of a broader treatment plan that includes lifestyle changes, psychological support and addressing genetic factors
Variables assessed include weight loss, dietary factors, and metformin exposure, all of which may independently influence gut microbiota composition and function
Wegovy is used for chronic weight management in overweight or obese adults with at least one related condition, such as Type 2 diabetes, high blood pressure, or high cholesterol